Evidence map›Paper›PMID 34314018›Full record

Trial reportCancer2021

Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.

Sagar Lonial, Hans C Lee, Ashraf Badros, Suzanne Trudel, Ajay K Nooka, Ajai Chari, Al-Ola Abdallah, Natalie Callander, Douglas Sborov, Attaya Suvannasankha and 9 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03525678 (A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody), which is not on this map. Cited by 76 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03525678 phase2completednot on this map

A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)

TypeinterventionalSponsorGlaxoSmithKlineRan2018 to 2024Enrolled221ConditionsMultiple MyelomaArmsBelantamab mafodotin frozen liquid, Belantamab mafodotin lyophilized powder
3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Extramedullary Disease-Achilles Heel in Myeloma?American journal of hematology · 2026
    Review
  14. Article
  15. Review
  16. Endless possibilities and how to exploit them? What is the optimal treatment sequence?Hematology. American Society of Hematology. Education Program · 2025
    Review
  17. Article
  18. Review
  19. An Update of the Appropriate Sequencing for Salvage Therapies in Multiple Myeloma.Mediterranean journal of hematology and infectious diseases · 2025
    Review
  20. Review

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Sagar LonialWinship Cancer Institute, Emory University, Atlanta, Georgia.ORCID 0000-0002-8322-9323
Hans C LeeDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ashraf BadrosGreenebaum Cancer Center, Bone Marrow Transplant Program, University of Maryland at Baltimore, Baltimore, Maryland.ORCID 0000-0003-1690-0188
Suzanne TrudelPrincess Margaret Cancer Center, Toronto, Ontario, Canada.
Ajay K NookaWinship Cancer Institute, Emory University, Atlanta, Georgia.ORCID 0000-0003-4165-6869
Ajai ChariIcahn School of Medicine at Mount Sinai, New York, New York.ORCID 0000-0002-0405-7480
Al-Ola AbdallahUniversity of Kansas Cancer Center, Fairway, Kansas.
Natalie CallanderCarbone Cancer Center, University of Wisconsin, Madison, Wisconsin.
Douglas SborovHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Attaya SuvannasankhaIndiana University Cancer Center, Indianapolis, Indiana.
Katja WeiselDepartment of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany.
Peter M VoorheesLevine Cancer Institute, Atrium Health, Charlotte, North Carolina.
Lynsey WomersleyGlaxoSmithKline, Stockley Park, United Kingdom.
January BaronGlaxoSmithKline, Upper Providence, Pennsylvania.
Trisha PiontekGlaxoSmithKline, Upper Providence, Pennsylvania.
Eric LewisGlaxoSmithKline, Research Triangle Park, North Carolina.
Joanna OpalinskaGlaxoSmithKline, Upper Providence, Pennsylvania.
Ira GuptaGlaxoSmithKline, Upper Providence, Pennsylvania.
Adam D CohenAbramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.

Funding

BLRD VA I01 BX004514CSRD VA I01 CX000623GlaxoSmithKline 205678
6 · The paper itself

Abstract

backgroundOn the basis of the DREAMM-2 study (ClinicalTrials.gov identifier NCT03525678), single-agent belantamab mafodotin (belamaf) was approved for patients with relapsed or refractory multiple myeloma (RRMM) who received ≥4 prior therapies, including anti-CD38 therapy. The authors investigated longer term efficacy and safety outcomes in DREAMM-2 after 13 months of follow-up among patients who received belamaf 2.5 mg/kg.

methodsDREAMM-2 is an ongoing, phase 2, open-label, 2-arm study investigating belamaf (2.5 or 3.4 mg/kg) in patients with RRMM who had disease progression after ≥3 lines of therapy and were refractory to immunomodulatory drugs and proteasome inhibitors and refractory and/or intolerant to an anti-CD38 therapy. The primary outcome was the proportion of patients that achieved an overall response, assessed by an independent review committee.

resultsAs of January 31, 2020, 10% of patients still received belamaf 2.5 mg/kg. Thirty-one of 97 patients (32%; 97.5% confidence interval [CI], 21.7%-43.6%) achieved an overall response, and 18 responders achieved a very good partial response or better. Median estimated duration of response, overall survival, and progression-free survival were 11.0 months (95% CI, 4.2 months to not reached), 13.7 months (95% CI, 9.9 months to not reached), and 2.8 months (95% CI, 1.6-3.6 months), respectively. Response and survival outcomes in patients who had high-risk cytogenetics or renal impairment were consistent with outcomes in the overall population. Outcomes were poorer in patients with extramedullary disease. In patients who had a clinical response and prolonged dose delays (>63 days; mainly because of corneal events), 88% maintained or deepened responses during their first prolonged dose delay. Overall, there were no new safety signals during this follow-up.

conclusionsExtended follow-up confirms sustained clinical activity without new safety signals with belamaf in this heavily pretreated patient population with RRMM.

Indexed as

Multiple MyelomaAntibodies, Monoclonal, HumanizedFollow-Up StudiesHumansProgression-Free SurvivalAntibodies, Monoclonal, Humanizedbelantamab mafodotinantibody-drug conjugateB-cell maturation antigenclinical activitymonoclonal antibodymultiple myeloma

Identifiers

PMID34314018
PMCPMC8597112

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.